Publications by authors named "Francesca Musio"
Advanced hepatocellular carcinoma (HCC) is the most frequent liver cancer. Immunotherapy has been explored in this disease in order to improve survival outcomes. Nowadays, scientific research is focusing especially on immune checkpoint inhibitors, in particular anti-PD1, anti-PD-L1 and anti-CTLA4 monoclonal antibodies (mAbs), as single-agent or in combination with other immunotherapy agents, target therapies, anti-vascular endothelial growth factor (VEGF) and other agents targeting specific molecular pathways.
View Article and Find Full Text PDFIntroduction: The association between pancreatic ductal adenocarcinoma (PDAC) and type 2 diabetes mellitus (DM2) has long been evaluated and the role of antidiabetic medications such as metformin has also been investigated. The objective of this study was to examine the association between insulin use and overall survival (OS) in patients with advanced PDAC and DM2.
Methods: We retrospectively collected data from 164 patients, including an exploratory cohort of 96 patients from Medical Oncology Unit, University Hospital and University of Cagliari, Italy, and a validation cohort of 68 patients from Medical Oncology of Modena University Hospital.
Article Synopsis
- Metastatic colorectal cancer (mCRC) is a complex disease, and this review focuses on how molecular characteristics influence treatment options for patients.
- The review discusses various studies that highlight the importance of molecular biomarkers, emphasizing that certain treatments like anti-EGFR drugs are best suited for patients with specific genetic profiles, while others like antiangiogenic therapies and immunotherapy show broad effectiveness.
- The conclusion draws attention to the progress being made in personalized treatment plans for mCRC, but stresses the need for more extensive research and trials to enhance patient care and outcomes.
Pancreatic ductal adenocarcinoma (PDAC) is associated with poor survival. Of all newly diagnosed patients, only about 20% can benefit from a potentially curative surgical resection, the remaining 80% presenting with unresectable locally advanced (LAPC) or metastatic (MPC) disease. Currently, there are limited therapeutic options for LAPC and MPC patients.
View Article and Find Full Text PDF